Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — J.P. Morgan Healthcare Conference 2022
34 slides from Bristol-myers Squibb's conference presentation, Jan 10, 2022
Slide 1: January 10, 2022 JP Morgan Presentation
January 10, 2022 JP Morgan Presentation
Slide 2: Forward Looking Statements and Non-GAAP Financial Information
Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actua
Slide 3: Strong Replacement Power Drives Growth Through the Decade
Strong Replacement Power Drives Growth Through the Decade 3 The Bristol Myers Squibb Story Continuing strong execution Expect growth through the decade Powerful drivers underpin our growth
Slide 4: Our Strategic Foundation
Our Strategic Foundation 4 A differentiated biopharma company focused on innovative medicines for patients with cancer and other serious diseases BEST OF BIOTECHBEST OF PHARMA Leading scientific innovationCollaborating at center of the biotech ecosystemLeveraging global scale and agilityDriven by th
Slide 5: Our Journey of Transformation
2007 — 2013 2014 — 2018 Today Our Journey of Transformation 5 Selective acquisitions and divestituresFocused exclusively on innovative medicines BioPharma Strategy Introduced Focus on Specialty Medicines Renewing the Portfolio Pioneering Immuno-OncologyDivested diabetes business Deepening innovation
Slide 6: Driving Growth Through the Decade — A Closer Look
Driving Growth Through the Decade — A Closer Look 6 ($12B – $14B) +$8B – $10B +$10B – $13B 2020 Revenues Key LOE Brands In-LineBrandsPrimarilyI-O & Eliquis 2025 Revenues New Product Portfolio Growth 2020 - 2025 Growth 2025 - 2029 2025 Revenues 2029Revenues LOE BrandsPrimarilyEliquis &Opdivo Addition
Slide 7: Strong Replacement Power Drives Growth Through the Decade
Strong Replacement Power Drives Growth Through the Decade 7 The Bristol Myers Squibb Story Continuing strong execution Expect growth through the decade Powerful drivers underpin our growth
Slide 8: Multiple Growth Drivers — More than Offset LOEs
Multiple Growth Drivers — More than Offset LOEs 8 NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval.Financial projections may contain non promoted sales, BMS promotes only according to label.*Non-GAAP: There is no reliable or reasonable estimable co
Slide 9: Foundation of Key In-line Brands Contribute $8B - $10B Growth from 2020-2025
Enabled bystrong cardiovascularinfrastructure Foundation of Key In-line Brands Contribute $8B - $10B Growth from 2020-2025 9 Maintain leadership in Melanoma & RCC Expand in metastatic disease incl. Lung & GI Lead evolution in early-stage disease A standard of careacross 11 tumors Drive leadership in
Slide 10: Multiple Growth Drivers — More than Offset LOEs
10 Multiple Growth Drivers — More than Offset LOEs 1. Drive Growth of New Product Portfolio $25B+ NRA revenuepotential in 2029 3. Advance Early-Stage Pipeline 50+assets 4. Leverage FinancialStrength $45B - $50B free cash flow*2022-2024 2. Launch Mid toLate-Stage Pipeline milvexian BCMA TCE cendakima
Slide 11: New Product Portfolio To Deliver $10B - $13B of Risk Adjusted Revenue in 2025
New Product Portfolio To Deliver $10B - $13B of Risk Adjusted Revenue in 2025 11 Growth driver #1 *Other includes: Abecma, Onureg, Inrebic, and rela+nivo FDC 2020 2025 Significantly de-risked portfolio: 9 new products: 6 approved, 3 filedIncreased confidence in expansion opportunitiesZeposia launch
Slide 12: Significant Growth By 2029 — $25B+ NRA Revenue Potential
Significant Growth By 2029 — $25B+ NRA Revenue Potential Growth driver #1 rela+nivo FDC deucravacitinib mavacamten $25B+ Non-Risk Adjusted** 2029 $4B+ $4B+ $4B+ $4B+ $3B+ $3B+ $1B+ $1B+ 2020 2025 2021 2022 2023 2024 2025 $10B - $13BRisk-adjusted sales Other* mavacamten Reblozyl Breyanzi Zeposia deuc
Slide 13: Reblozyl: Differentiated Medicine for Anemia — $4B+ Opportunity
Reblozyl: Differentiated Medicine for Anemia — $4B+ Opportunity 13 Notes regarding patient #s: MF & MDS represent combined U.S./EU5 estimates; beta-thal represents U.S. only; noted for each indication in launch year for lead market (e.g. U.S.); patient #s do not include growth of epidemiology over t
Slide 14: Mavacamten: First-in-Class Medicine in Hypertrophic Cardiomyopathy — $4B+ Opportunity
Mavacamten: First-in-Class Medicine Treating Underlying Disease in Hypertrophic Cardiomyopathy — $4B+ Opportunity 14 1U.S./EU5 market prevalenceNRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approval Deucravacitinib Rela+Nivo FDC Growth driver #1 Mavacamt
Slide 15: Deucravacitinib: Selective TYK2 Inhibitor — $4B+ Opportunity
Deucravacitinib: Selective Inhibitor of TYK2 with Potential Across Multiple Immune-Mediated Diseases — $4B+ Opportunity 15 NRA: Non-Risk Adjusted sales subject to positive registrational trials and health authority approvalEpidemiology represents combined U.S./EU5 patient prevalence numbers Rela+Niv
Slide 16: Relatlimab+nivolumab: First in Class LAG-3 + PD-1 Inhibitor — $4B+ Opportunity
Relatlimab+nivolumab: First in Class LAG-3 + PD-1 Inhibitor — $4B+ Opportunity 16 Growth driver #1 Mavacamten Deucravacitinib Opportunity for relatlimab + Opdivo to be 1st Fixed-dose Combination (FDC) Therapy of Novel LAG-3-blocking Antibody + Anti-PD1Near-term launch opportunity in 1L metastatic me
Slide 17: Multiple Growth Drivers — More than Offset LOEs
17 Multiple Growth Drivers — More than Offset LOEs 1. Drive Growth of New Product Portfolio $25B+ NRA revenuepotential in 2029 3. Advance Early-Stage Pipeline 50+assets 4. Leverage FinancialStrength $45B - $50B free cash flow*2022-2024 2. Launch Mid toLate-Stage Pipeline milvexian BCMA TCE cendakima
Slide 18: Focused on Disease Areas with Large Commercial Potential
Focused on Disease Areas with Large Commercial Potential 18 milvexian cendakimab iberdomide CC-92480 BCMA TCE bempeg FRa ADC 7 Mid to Late-Stage Pipeline Assets $20B+ $80B+ Growth driver #2 $40B+ $75B+ SignificantCommercial Potential 50+Early-Stage Assets Thrombosis$19B+ HF $3B+ Renal $7B+ Liver $1B
Slide 19: Milvexian: Significant Opportunity for Next Generation Anti-Thrombotic
19 Milvexian: Significant Opportunity for Next Generation Anti-Thrombotic – $5B+ Opportunity Growth driver #2 Optionality for Ph3 program pending SSP Ph2 results Anti-platelets1SSPACSCAD/PAD Factor Xa1VTEAFIB Milvexian$5B+NRA sales 1Represents indications with majority of usage Potential Universe of
Slide 20: CELMoD Agents Have the Potential to Replace the Current Foundation of Care
CELMoD Agents Have the Potential to Replace the Current Foundation of Care 20 1L 2L 3L 4L Revlimid today Pomalyst today Replace Revlimid as foundation of frontline multiple myeloma treatment iberdomide vision Replace Pomalyst as foundation of treatment in relapsed refractory multiple myeloma (RRMM)
Slide 21: MORAb-202: A Novel Folate Receptor Alpha ADC
MORAb-202: A Novel Folate Receptor Alpha ADC 21 In partnership with EisaiTumors of interest include ovarian, NSQ NSCLC, breast, endometrialHigh addressable population based on range of FR expression Differentiated payload (eribulin) Demonstrated single agent clinical activity across multiple tumor t
Slide 22: Multiple Growth Drivers — More than Offset LOEs
22 Multiple Growth Drivers — More than Offset LOEs 1. Drive Growth of New Product Portfolio $25B+ NRA revenuepotential in 2029 3. Advance Early-Stage Pipeline 50+assets 4. Leverage FinancialStrength $45B - $50B free cash flow*2022-2024 2. Launch Mid toLate-Stage Pipeline milvexian BCMA TCE cendakima
Slide 23: Leading Drug Discovery Platforms Drive Our Deep Ph1 / Ph2 Pipeline
Leading Drug Discovery Platforms Drive Our Deep Ph1 / Ph2 Pipeline 1 In development for solid tumors and hematology2 BMS has an exclusive option to license and/or option to acquire3 IND/CTA approved BCMA TCE GSPT1 CELMoD(CC-90009) Anti-SIRPα1(CC-95251) BET Inhibitor1(CC-90010) BET Inhibitor (CC-9577
Slide 24: Internal R&D Strengths are Amplified Through Extensive Network of External Partnerships
Internal R&D Strengths are Amplified Through Extensive Network ofExternal Partnerships 24 >85Active Collaborations 4INDs Filed 2021 12Licenses Optioned 2021 EXEMPLAR MMPACT Mechanisms of Cancer Resistance TumorMicro- Environment Immuno-Oncology & Cell Therapy Oncogenesis Discovery Biothera-peutics S
Slide 25: Multiple Growth Drivers — More than Offset LOEs
25 Multiple Growth Drivers — More than Offset LOEs 1. Drive Growth of New Product Portfolio $25B+ NRA revenuepotential in 2029 3. Advance Early-Stage Pipeline 50+assets 4. Leverage FinancialStrength $45B - $50B free cash flow*2022-2024 2. Launch Mid toLate-Stage Pipeline milvexian BCMA TCE cendakima
Slide 26: Strong Cash Flow Provides for Significant Financial Flexibility
Strong Cash Flow Provides for Significant Financial Flexibility 26 * Non-GAAP: There is no reliable or reasonable estimable comparable GAAP metric for this non-GAAP forward-looking information** Future dividend payouts subject to board authorization Prioritizing Business Development Strengthening th
Slide 27: Business Development Remains a Top Priority to Complement the Portfolio
Deals over the last 18 months A further diversified pipeline Business Development Remains a Top Priority to Complement the Portfolio for Long-Term Growth 27 Oncology Hematology Immunology Cardiovascular Neurology Will continue to execute BD in leading scientific areas of high unmet medical need with
Slide 28: Strong Replacement Power Drives Growth Through the Decade
Strong Replacement Power Drives Growth Through the Decade 28 The Bristol Myers Squibb Story Continuing strong execution Expect growth through the decade Powerful drivers underpin our growth
Slide 29: 2021 Key Milestones: Delivered on Our 2021 Commitments
2021 Key Milestones Opdivo (+/- Yervoy) U.S./EU expected approvals:1L RCC (9ER)1L GC (649, O+Chemo)adj Eso (577)adj MIBC (274) 1L Esophageal (CM-648) Opdivo return to annual growth Relatlimab 1L Melanoma w/Opdivo Ph3 Breyanzi 3L+ LBCL U.S.3L+ LBCL EU approval1 2L TE LBCL2L TNE LBCL 3L+ CLL2 Delivere
Slide 30: Portfolio Depth Provides Significant Near-term Catalysts
2022 Key Milestones Opdivo (+/- Yervoy) U.S./EU expected approvals:1L ESCC (CM-648)Neo-adj lung EFS (CM-816) (U.S.) relatlimab + Opdivo FDC 1L melanoma U.S. approvalInitiation 2L+ CRC Ph3 bempeg 1L melanoma1L renal1L bladder Breyanzi 2L LBCL U.S. approval3L+ LBCL EU approval Abecma 2L+ MM (KarMMa-2)
Slide 31: Critical 2022 & 2023 Deliverables to Unlock Value of New Product Portfolio
Critical 2022 & 2023 Deliverables to Unlock Value of New Product Portfolio 31 Enable expansion forReblozyl through successful1L MDS COMMANDS trial deucravacitinib mavacamten Deliver successful launch of mavacamtenover the next year Establish deucravacitinib as oral of choice in moderate to severe Ps
Slide 32: 2022 Net Sales Guidance
\2022 Net Sales Guidance 2022 Net Sales Guidance Total Company Sales ~$47.0B or low single-digit growth Key LOE Brands ~$10.5B or double-digit decline Continuing Business ~$36.5B or low double-digit growth 2022 Revenue Growth of Continuing Business Offsets Decline of Key LOE Brands, Coupled with Str
Slide 33: Strong Replacement Power Drives Growth Through the Decade: In Summary
Significant growth potential of Continuing Business through Key LOEs Rapidly advancing pipeline with 7 mid-stage programs and over 20 POC decisions in the next 3 years 9 new product launches – 4 medicines with $4B+ non-risk adjusted sales potential* Financial strength for continued investment in Bus
Slide 34: January 10, 2022 JP Morgan Presentation
January 10, 2022 JP Morgan Presentation
Bristol Myers Squibb — J.P. Morgan Healthcare Conference 2022 on 6ix